Autonomix Medical (NASDAQ:AMIX) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Autonomix Medical (NASDAQ:AMIX) to a strong sell rating in a research report sent to investors on Saturday morning.

Several other brokerages also recently weighed in on AMIX. Weiss Ratings raised Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $42.00.

Autonomix Medical Stock Down 5.5%

NASDAQ:AMIX opened at $5.32 on Friday. Autonomix Medical has a 52 week low of $2.44 and a 52 week high of $32.55. The stock’s 50-day moving average price is $6.34 and its 200-day moving average price is $7.56. The stock has a market capitalization of $5.16 million, a PE ratio of -0.13 and a beta of -1.17.

Autonomix Medical (NASDAQ:AMIX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. Sell-side analysts expect that Autonomix Medical will post -20.17 earnings per share for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.